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aggressive medical therapy in recent years, a review of the 
fate of diabetics in dialysis units since 1972 reveals that these 
patients have had significant morbidity and mortality. We 
still have a long way to go in order to achieve more ideal out-
comes for our patients. Most of the diabetic ESRD patients 
are still maintained by MHD, but they can choose other mo-
dalities of RRT such as chronic ambulatory peritoneal dialysis 
(CAPD), kidney and kidney plus pancreas transplantation. 
The results of different studies and national registries on the 
mortality and morbidity of ESRD patients being maintained 
on different modalities of dialysis are conflicting. It can be 
concluded that the two modalities of dialysis (CAPD and 
MHD) are almost comparable in terms of survival. The recent 
suggestions for nocturnal daily hemodialysis, short daily he-
modialysis, and an integrative care approach for the man-
agement of diabetics with ESRD provides better promise for 
these patients.  Copyright © 2007 S. Karger AG, Basel 
 Introduction 
 The prevalence of diabetes mellitus (DM) is very high 
worldwide. According to the World Health Organiza-
tion (WHO), in 2000 the worldwide prevalence of DM 
was 171,000,000. In 2005, the WHO estimated that by 
2030 the worldwide prevalence of diabetes will reach 
366,000,000  [1] . End-stage renal disease (ESRD) second-
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 Abstract 
 The prevalence of diabetes mellitus (DM) is very high world-
wide. According to the World Health Organization in 2000 
the worldwide prevalence of DM was 171,000,000. Diabetic 
nephropathy is a major vascular complication of DM. If DM 
is not treated early and adequately, many diabetic patients 
may reach end-stage renal disease (ESRD) secondary to ad-
vanced irreversible diabetic nephropathy. In many countries 
diabetic nephropathy has become the single most frequent 
cause of prevalent ESRD patients undergoing maintenance 
hemodialysis (MHD). In the early era of renal replacement 
therapy (RRT) by means of intermittent hemodialysis the 
prognosis of diabetic patients undergoing MHD was ex-
tremely poor and disappointing. While the prognosis of pa-
tients suffering from diabetic ESRD and maintained by 
chronic intermittent dialysis has greatly improved, the reha-
bilitation rate and survival of these patients continue to be 
worse than those of non-diabetic patients. A preexisting se-
verely compromised cardiovascular condition, vascular ac-
cess problems, diabetic foot disease, interdialytic weight 
gain, and intradialytic hypotension explain most of the less 
favorable outcome. Despite improved techniques and more 
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ary to advanced diabetic nephropathy (DN) requiring re-
nal replacement therapy (RRT) is one of the most serious 
complications of DM. According to the 2005 United 
States Renal Data System (USRDS) estimates, the num-
ber of patients suffering from DN and ESRD who are ad-
mitted to dialysis units is increasing dramatically. The 
incidence of reported ESRD was 4.3% with type-1 DM 
and 40.5% with type-2 DM  [2] .  Figures 1 and  2 reveal the 
incidence and prevalence of DM in dialysis according to 
the USRDS. The incidence of patients with DN requiring 
dialysis is globally significant. 36 and 22% of incident di-
alysis patients in Germany and Australia, respectively, 
have ESRD due to DN  [3] . This figure is no less in devel-
oping countries, for instance in Iran 25.2% of incident 
dialysis patients are reported to have ESRD as a result of 
DN  [4] .  Figure 3 shows the incidence of RRT according 
to different registries  [5] . Indeed it can be claimed that 
many developed and developing countries are in the 
midst of an epidemic of ESRD. Part of this epidemic can 
be explained by the increase in life expectancy that has 
occurred worldwide in the past two centuries  [6] . Cur-
rently the effect of general health improvement is more 
pronounced in developing countries. For example in 
Iran, a country which is considered to be a medium hu-
man development country, the life expectancy at birth 
increased to 70.1 years in 2002. As a result, the total pop-
ulation has increased from 33.4 million in 1975 to 68.1 
million in 2002. In Pakistan which is considered to be a 
low human development country, the total population in 
1975 was 70.3 million, and in 2002, it increased to 149.9 
million. These figures for countries with high human de-
velopment, e.g. Belgium, have changed less dramatically; 
the population was 9.8 million in 1975 and 10.3 million 
in 2002. In the USA the population grew from 220.2 mil-
lion in 1975 to 291.0 million in 2002  [7] . The remarkable 
population growth which is being observed in developing 
countries is a welcome consequence of decreased mortal-
ity during infancy and young adulthood, better nutrition 
and the control of infections, and improved education. 
An unwanted consequence of these improvements has 
been the emergence of chronic metabolic diseases includ-
ing ESRD. It can be concluded from this fact that, in the 
third millennium, the global epidemic of ESRD will be of 
importance worldwide and more importantly in develop-
ing countries. This fact may not be quite evident as the 
prevalent worldwide ESRD data are reported from pa-
tients who are undergoing maintenance hemodialysis 
(MHD). In developing countries, the number of patients 
reaching dialysis is dramatically less than the number of 
patients who die before reaching dialysis. Another major 
problem in the developing world is the lack of reliable sta-
tistics regarding the incidence and prevalence of diseases, 
morbidity, and mortality.
 Even for the developed countries, providing enough 
funds for management of RRT has not been easy, and cer-
tainly for the developing countries, it is a dream. These 
facts impact the fate of diabetics in the dialysis unit and 
elsewhere. Indeed it is very hard to improve the fate of any 
 Fig. 1. The incident counts and adjusted incidence rates by primary diagnosis in ESRD patients according to 
the USRDS. 
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disease in the presence of poverty. Even if newer technol-
ogy becomes cheaper in the future, the scarcity of funds, 
wealth and infrastructure in the underdeveloped world 
will be a barrier to changing the fate of the diabetic pa-
tient.
 Changing the Fate of Diabetics in the Dialysis Unit 
 In a symposium on diseases of kidney reported in 1971 
Williem J. Kolff was quoted as saying in 1938, ‘Gradually 
the idea grew in me that if we could only remove 20 g of 
urea and other retention products per day we might re-
lieve this man’s nausea and that if we did this from day to 
day, life might still be possible’  [8] . Dunea  [8] started his 
article after this statement and wrote, ‘Within three de-
cades dialysis has revolutionized the field of nephrology 
and opened new vistas in the treatment of uremia. … Yet, 
dialysis gradually outgrew its difficult beginnings and 
became established among the great medical achieve-
ments of our age.’ In this article there is no mention of the 
diabetic ESRD patient. A year later in 1972, Ghavamian 
et al.  [9] report on 9 patients with renal failure resulting 
from DN who were treated by hemodialysis. The average 
duration of diabetes was 21 years and the average dura-
tion of nephropathy was 26 months. One patient survived 
for more than 3 years. The others survived 9, 20, 19, and 
13 months, respectively. Overall mortality was 78% at the 
end of 1 year. All patients had problems with clotting or 
infection of the bloodstream access routes or both. All 
had further visual deterioration. Neuropathy was not ac-
celerated. Muscle wasting, hypoproteinemia, and fluid 
overload were common. Dialysis for such patients may be 
considered as a palliative measure with little likelihood 
of long-term survival or improvement in quality of life. 
Four of their patients were male, 3 female, and the age 
ranged from 26 to 49 years. The duration of proteinuria 
was 1–5 years.
 Fig. 2. Prevalent count and adjusted rates by primary disease according to the USRDS 2005 annual data re-
port. 
 Fig. 3. Year 2000 percentage of incident renal replacement pa-
tients with diabetes as the primary diagnosis according to na-
tional registries. Modified with kind permission from Prof. Lo-
catelli. 
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 It is evident that the problems facing diabetic ESRD 
patients are still the same, maybe with less ophthalmo-
logic problems but more atherosclerotic cardiovascular 
disease (CVD) and congestive heart failure.
 This was the fate of a diabetic ESRD patient in a devel-
oped country such as the USA in the early 1970s. There 
is no doubt that in those days there was no hope even for 
non-diabetic ESRD patients to have access to dialysis 
treatment even for one day in many countries. Certainly 
at present we are equipped with much better technology, 
medications and understanding of the pathophysiology 
of the disease, but still we have a long way to go in order 
to achieve more ideal outcomes for diabetic ESRD pa-
tients.
 The situation for all ESRD patients was the same until 
the passage of public law 92-603(HR1) which allowed the 
federal government to fund the treatment of approxi-
mately 85–90% of Americans with ESRD.
 Approximately 13,000 patients were being treated by 
intermittent hemodialysis and 200–300 by peritoneal di-
alysis when the law became effective in July 1973. Addi-
tionally, about 2,400 patients/year received kidney trans-
plants. Publicity related to passage of the bill resulted in 
a large influx of new patients. The potential impact of the 
law is put into perspective by envisioning 10,000 to 13,000 
new patients entering treatment each year  [10] . Neverthe-
less, 9 months after passage of the law, July 1973, many 
serious difficulties in implementation remained. In his 
article discussing the major unwanted effects of hemo-
dialysis treatment in all patients, Ginn  [10] concluded 
that major problems remained regarding:  (1) nutrition; 
(2) hypertension; (3) anemia; (4) bone disease in uremia; 
(5) pericarditis; (6) blood access; (7) hemodialysis equip-
ment, and (8) water treatment in hemodialysis.
 Although there is nothing specific related to diabetic 
ESRD patients from those days, the general status of di-
alysis and its problems did exist for all ESRD patients. To 
realize the different status of the early era of dialysis, 
Ginn  [10] stated, ‘Dialysis patients often tolerate very low 
hematocrit values remarkably well, in part because the 
myocardium becomes conditioned by chronic anemia, 
and in part because red cell levels of 2,3-diphosphoglyc-
erate (DPG) increases in anemia, especially during an-
drogen therapy. Contrarily, if serum inorganic phosphate 
is lowered below normal range by dialysis and/or alumi-
num gels, then 2,3-DPG levels are reduced. Increased lev-
els of 2,3-DPG improve tissue oxygenation by decreasing 
the affinity of hemoglobin for oxygen. On the other hand, 
conventional dialysis usually induces a transient com-
bined respiratory and metabolic alkalosis in patients who 
often are initially mildly acidotic. Acidosis increases oxy-
gen dissociation whereas alkalosis reduces oxygen disso-
ciation. Continued frequent hemodialysis generally ben-
efits but does not eliminate the anemia. Because of in-
creased needs, regular iron supplements should be given. 
Some patients respond to oral iron administration. Oth-
ers require intravenous iron, e.g., up to 50 ml of Imferon 
infused over several hours. Meticulous care in returning 
all blood from the dialyzer and minimizing the number 
of laboratory tests are obviously important. Androgens in 
large doses, such as 400 mg of testosterone enanthate per 
week, have been found to benefit many patients who still 
have kidneys, but their effect in anephric patients is un-
predictable. Androgenic side effects have not been severe, 
even in female patients, if preparations are used which 
minimize such effects. If they do occur, however, they are 
irreversible.’
 These statements are contrary to our understanding 
today. Anemia is not tolerated by the medical commu-
nity. Regardless of the benefit of 2,3-DPG no one will ac-
cept hyperphosphatemia, and the recommendation is to 
bring serum phosphate down to normal for many differ-
ent reasons including secondary hyperparathyroidism 
which can by itself adversely effect anemia. The use of 
androgen is not recommended, and finally, currently ac-
idosis is considered very harmful and bicarbonate dialy-
sate is the ideal solution for patients on dialysis.
 As can be seen, insight into the etiology of anemia in 
ESRD has come a long way. While the trade-off hypoth-
esis could in part explain the different approach in the 
early 1970s in the management of patients undergoing 
MHD  [11] , at present we are equipped with a more effec-
tive armamentarium in our fight against uremia. We do 
not have to wait for one organ to be sacrificed for the sur-
vival of another organ, such as the bone sacrificing part 
of its structure and quality, in order for the body to toler-
ate and decrease the adverse effects of renal failure on 
organs such as the nervous system. Gradually some skep-
ticism grew about this phenomenon. A decade later Fine 
 [12] wrote: ‘A number of physiologic adaptations in 
chronic uremia serve to palliate the functional loss im-
posed on the kidneys by progression of the toxic aspects 
of the disease process. Logically, therapeutic strategies 
should seek to reinforce the adaptive responses while sup-
pressing or retarding the toxic progression. However, 
such strategies are not without pitfalls and limitations.’
 Although the role of the kidney in erythropoiesis was 
known for a long time, there was clearly no knowledge 
about clinical use of erythropoietin in those days  [13] . It 
was not until the results of a combined phase I and II 
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clinical trial were published that erythropoietin therapy 
became clinically relevant  [14] . Up to that time 25% of 
150,000 ESRD patients on dialysis required intermittent 
red cell transfusions  [15] . It is easy to assume that those 
patients would have developed unwanted events such as 
blood-borne infections, hepatitis, iron overload, further 
bone marrow suppression and HLA antigen sensitiza-
tion.
 Considering the above-mentioned facts, one can imag-
ine how much the fate of diabetic patients has been under 
constant change in the dialysis unit since 1970.
 Today diabetes is the most common global cause of 
chronic kidney disease (CKD), present in one fourth to 
two thirds of all patients with renal impairment  [4, 16] . 
Anemia is more severe in diabetic ESRD patients and 
2–3 times more prevalent in diabetics with CKD and 
ESRD than in non-diabetics with the same degree of re-
nal impairment  [17] . It has recently been recognized that 
in diabetic patients anemia is seen not only in pre-termi-
nal renal failure, but frequently also in patients with only 
minor derangement of renal function  [18] . A major cause 
of anemia is an inappropriate response of erythropoietin 
to anemia. Additional factors are iron deficiency and iat-
rogenic factors, e.g. ACE inhibitor treatment. Because 
most of the late complications of diabetes involve isch-
emic tissue damage, it would intuitively be plausible that 
treatment with human recombinant erythropoietin 
should be beneficial to ESRD patients. With regard to the 
question of the management of anemic patients with 
DN, there is not sufficient evidence from controlled clin-
ical trials to come up with a satisfactory answer. The 
question remains whether correction of anemia with 
erythropoietin treatment is beneficial with respect to di-
abetic end-organ damage in patients with diabetic ESRD. 
The new KDOQI anemia guidelines published in May 
2006 define anemia as a Hb of  ! 13.5 g/dl for males and 
 ! 12.0 g/dl for females and a target Hb of  6 11 g/dl with 
caution when intentionally maintaining Hb at  1 13 g/dl. 
For target iron stores, the recommendation is a TSAT of 
at least 20%, and a lower ferritin limit of 200 ng/ml in 
HD-CKD and 100 ng/ml in non-HD-CKD  [19] . A fer-
ritin level of  1 500 ng/ml is not recommended. Adjuvant 
therapy such as  L -carnitine and ascorbate are not rou-
tinely recommended because of low quality evidence, 
lack of efficacy, and also safety concerns regarding ascor-
bate. Androgen use is not recommended as current 
guidelines reflect serious safety concerns. Evidence for 
efficacy is low quality.
 A hyporesponse to an erythropoiesis-stimulating 
agent (ESA) and iron therapy can occur. The patient with 
anemia and CKD should undergo evaluation for specific 
causes of hyporesponse if the Hb level is persistently 
 ! 11 g/dl, and if the ESA dose is equivalent to epoetin of 
 1 500 IU/kg/week. Factors most commonly associated 
with persistent failure to achieve target Hb levels for at 
least 6 months despite ESA therapy include persistent 
iron deficiency, frequent hospitalization, hospitalization 
for infection, temporary catheter insertion, permanent 
catheter insertion, hypoalbuminemia, and elevated C-re-
active protein (CRP) levels. Other contributing factors 
include pancytopenia/aplastic anemia, hemolytic ane-
mia, chronic blood loss, cancer, chemotherapy, or radio-
therapy, inflammatory diseases, acquired immune defi-
ciency syndrome, and infection.
 Nowadays susceptibility to infection is more common 
in countries where the dialysis dose is less than the rec-
ommended dose of the HEMO study  [20] . Financial re-
strictions and a shortage of manpower and equipment 
especially in diabetic ESRD patients play a role in the sus-
ceptibility to infections. In dialysis units in developed 
countries, tuberculosis has been reported in immigrants 
from endemic areas; this is especially more common in 
DN  [21] . Except in patients suffering from HIV and 
ESRD, more efficient dialysis and as a result better nutri-
tion has decreased the incidence of TB in diabetics in the 
dialysis unit.
 Despite significant improvements in technology and 
the knowledge of RRT, the morbidity and mortality of 
ESRD patients remains high. Poor nutrition and protein 
and calorie intake are major contributing factors for pro-
tein-energy malnutrition (PEM). The recommendations 
for better and healthier nutrition have not changed since 
the early 1970s. The recommendation was: ‘… to prevent 
(or to correct) body protein deficiency, to provide ade-
quate calories … usually 1–1.5 g of high biologic value 
protein per kg/day’  [10] . Although the importance of ad-
equate nutrition and calories has been recognized since 
the 1970s, for various reasons inadequate nutrition has 
continued to be a problem. There are many causes of pro-
tein calorie malnutrition in maintenance dialysis pa-
tients. The three major causes are probably a low nutrient 
intake, intercurrent or underlying illnesses, and the di-
alysis procedure itself  [22] . In underdeveloped countries, 
a shortage of equipment and manpower plus the expense 
result in inadequate dialysis. Sometimes uneducated pa-
tients decide to eat less so as to have less waste byproduct 
of protein. This poor nutrition decreases the blood urea 
measured, so the patients think their need for dialysis 
will be less, while it is known that low serum nitrogen 
levels as a result of PEM are associated with an increased 
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mortality in ESRD patients undergoing MHD. Even in 
developed countries the prescribed dose of dialysis is 
usually not adequate. The result of inadequate dialysis is 
loss of appetite and anorexia leading to decreased protein 
and calorie intake. Diabetic patients appear to be more 
sensitive than non-diabetics to inadequate dialysis  [23] . 
PEM is a common phenomenon in maintenance dialysis 
patients and a risk factor for poor quality of life and in-
creased morbidity and mortality, including cardiovascu-
lar death in these individuals  [24] . To explore the effects 
of CRP and the normalized protein catabolic rate on se-
rum albumin and creatinine, the laboratory data from 
364 hemodialysis patients were analyzed for 6 consecu-
tive months using a multivariate mixed model with con-
servative biases. The conclusion was that inflammation 
and dietary protein intake exert statistically significant 
and clinically meaningful competing effects on serum 
albumin and creatinine over time. Therapeutically, the 
model would predict that by increasing the normalized 
protein catabolic rate from 0.8 to 1.2 g/kg/day, one might 
expect an increase in albumin of approximately 0.5 g/dl 
and an increase in creatinine of approximately 4.4 mg/dl 
over a 6-month period, all else being equal  [25] . Athero-
sclerotic CVD, PEM and the wasting syndrome are com-
mon in patients with ESRD and contribute to the in-
creased morbidity and mortality of these patients. Serum 
albumin, CRP, and interleukin-6 predict malnutrition 
 [26] . In a random sample of 4,025 patients the prevalence 
of coronary heart disease was 38%. The incidence was 
significantly more common in diabetic patients (46.4%) 
than in non-diabetic patients (32.2%). Much of the car-
diac pathology is acquired even prior to establishment of 
end-stage renal failure  [27] . In another study about causes 
of death among patients with ESRD, 84 diabetic and 74 
non-diabetics were evaluated by coronary angiography. 
Triple vessel coronary artery disease was significantly 
more common among the diabetic subjects (27 vs. 12%, 
p = 0.005)  [28] .
 Glycemic control appears to impact the survival of di-
abetic ESRD patients. In a study investigating 150 dia-
betic ESRD patients, it was found that good glycemic con-
trol (HgbA1c  ! 7.5%) predicted better survival  [29] . In 
order to determine the optimal target for glycemic con-
trol in diabetic dialysis population, the DaVita national 
dialysis database was analyzed. Of 82,933 patients under-
going MHD in DaVita outpatient clinics over 3 years, 
26,187 MHD patients had HbA1c measurements at least 
once. Raw mortality data revealed that lower HbA1c val-
ues were associated with higher all-cause mortality rates 
( fig. 4 ); accordingly, unadjusted survival analyses indi-
cated lower death risks in MHD patients with higher 
HbA1c values. Similar findings were noted with cardio-
vascular death. However, after adjusting for potential 
confounders including case-mix, age, gender, race, dialy-
sis vintage and dose, comorbidity, and surrogates of the 
malnutrition-inflammation complex syndrome (MICS), 
HgbA1c values of  1 8% were incrementally associated 
with higher all-cause and cardiovascular death risk. The 
authors concluded that the greatest survival was observed 
with HbA1c of  ! 8% ( fig. 5 )  [30] .
 Fig. 4. Raw unadjusted mortality rate.  Fig. 5. Mortality rate adjusted for case mix and malnutrition-
inflammation complex syndrome (MICS). 
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 Diabetic ESRD patients on dialysis respond to insulin 
differently. The risk for hypoglycemia increases during 
hemodialysis sessions. The compensatory homeostatic 
response to hypoglycemia may increase the risk of abnor-
mal blood pressure regulation. Similarly, if glucose-free 
dialysates are used, then diabetic patients may become 
hypoglycemic, as insulin is not removed during dialysis 
and there may be an inappropriate neuroendocrine re-
sponse  [31] .
 In a randomized, placebo-controlled, unblinded, 
cross-over study of 44 hemodialysis patients, 34 patients 
without diabetes and 10 patients with diabetes were al-
located to treatment with and without glucose in the di-
alysate during two 10-week periods. Blood pressure and 
blood glucose levels were determined 5–8 times in each 
dialysis session during both periods. Systolic and dia-
stolic blood pressures decreased with glucose in the di-
alysate in patients with ESRD, presumably because of 
insulin-induced vasodilatation in patients without dia-
betes. Blood glucose level regulation improved in the di-
abetic subgroup, and blood glucose levels were not great-
er in patients with diabetes with glucose in the dialysate 
 [32] .
 The presence of autonomic dysfunction can also im-
pair patients’ ability to maintain blood pressure following 
a large degree of fluid removal by ultrafiltration. The in-
cidence of intradialytic hypotension has been reported to 
be from 5 to 40% of all the patients on MHD  [31] . As dys-
function of the autonomic nervous system is more com-
mon in diabetic ESRD patients, intradialytic hypotension 
is more common in this subgroup of dialysis patients  [33] . 
Activation of the Bezold-Jarisch reflex, which involves 
decreased sympathetic and increased parasympathetic 
nervous system activity, may also occur with ultrafiltra-
tion, causing sudden intradialytic hypotension  [34] . A 
less common and much more obscure derangement of 
blood pressure control during hemodialysis in ESRD pa-
tients is increases in blood pressure, that is, intradialytic 
hypertension. This syndrome is multifactorial and the 
pathogenesis is not clearly understood  [35] . Most patients 
with ESRD on MHD have chronic hypertension. There is 
no disagreement on the role of hypertension as a risk fac-
tor for increased cardiovascular or cerebrovascular events 
in the general population  [36] . Despite the accepted dan-
ger of high blood pressure in the general population, 
there is evidence that in ESRD patients there is a link be-
tween low blood pressure and poor survival  [37] . This 
phenomenon has been referred to as reverse epidemiol-
ogy, and besides hypertension, other known risk factors 
behave in opposite ways in patients with ESRD as a result 
of MICS. Components of reversible epidemiology are 
shown in  table 1 .
 There are many different intradialytic and interdia-
lytic complications that diabetic ESRD and ESRD pa-
tients have, albeit occasionally they are more pronounced 
in diabetic ESRD patients. Adverse cardiovascular effects 
of hyperphosphatemia may be more extensive and severe 
in diabetic ESRD patients because of the unwanted ef-
fects of nephropathy on the cardiovascular system prior 
to the establishment of ESRD.
 The well-being of diabetic patients is greatly influ-
enced by diabetic foot disease. In one report, diabetic foot 
disease resulted in amputation of lower limbs in 14% of 
ESRD patients  [38] . The association of diabetic foot le-
sions with advanced DN may be explained by the long 
duration of diabetes, macroangiopathic and neuropathic 
complications or a combination of both  [39] .
 Another major determinant of the fate of diabetic 
ESRD patients includes hemodialysis equipment. In the 
early 1970s approximately 50–55% of patients were being 
treated by coil dialyzers, some 25–30% by parallel plate 
units, and about 20% by hollow fiber capillary dialyzers 
 [10] . At present, dialyzers are more biocompatible and ef-
ficient with lower capacity facilitating more efficient di-
alysis in comparison with the past  [40] .
 Patient survival in diabetics on maintenance dialysis 
is lower than that seen in non-diabetics. As noted in the 
2005 USRDS report, approximately 25% of diabetic ESRD 
patients survived 5 years after the initiation of dialysis 
 [2] . Survival also varies inversely with age, being best in 
young normotensive patients without any clinical CVD 
 [5] . The USRDS excludes patients who died within the 
first 90 days of the initiation of dialysis, so the result is of 
limited value  [2] . The situation is comparable in other 
countries. In Iran, the dialysis outcome was reported for 
Table 1. Components of reverse epidemi-
ology in dialysis patients
Obesity
Hypercholesterolemia
Hypertension
Homocysteine
Creatinine
Calcium
Potassium
Iron
Advanced glycation end products
Others: leptin, bicarbonate
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68 patients with DN and 66 non-diabetics. The mortality 
was 52.9% in diabetic patients. Survival seems somewhat 
better because of the selection criteria  [41] . The adequacy 
of dialysis and the decrease in nutritional status may also 
be contributors to the worse outcome in diabetics. Dia-
betic patients appear to be more sensitive than non-dia-
betics to inadequate dialysis prescriptions.
 The morbidity associated with insufficient dialysis in 
diabetics may be mediated through anorexia, leading to 
decreased caloric and protein intake. Death by withdraw-
al from dialysis is also more likely to occur in diabetics.
 MHD is the most common dialysis modality used 
worldwide  [2] . For many reasons, different modalities 
may be more ideal for different patients. In a national co-
hort study of 1,041 patients starting dialysis (274 patients 
receiving peritoneal dialysis and 767 patients receiving 
hemodialysis at baseline) it was concluded that the risk of 
death in patients with ESRD undergoing dialysis depend-
ed on dialysis type  [42] . It has been suggested that short 
daily hemodialysis will improve the quality of life, rate of 
hospitalization and mortality  [43] . It has been suggested 
that home daily nocturnal hemodialysis may have the 
highest survival for diabetic patients on MHD  [44] . Noc-
turnal hemodialysis offers a high dose of dialysis, im-
proves biochemical parameters and quality of life. De-
spite the significant losses, in a study of 24 patients under 
daily nocturnal hemodialysis, protein malnutrition was 
not seen. Most of the patients were anabolic  [45] . Further 
studies are needed to see how short daily hemodialysis or 
daily nocturnal hemodialysis affect diabetic ESRD pa-
tients.
 Finally, it has been suggested that the different mo-
dalities of RRT should be complementary and not com-
petitive. For this reason an integrative care approach is 
necessary for ESRD patients whereby, when appropriate, 
patients are started on peritoneal dialysis, followed by 
kidney transplantation whenever possible and trans-
ferred timely to hemodialysis when peritoneal dialysis-
related problems arise. This approach would perhaps en-
able us to make use of the entire RRT arsenal ( table 2 ; 
 fig. 6 )  [46] .
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Table 2. The integrated care concept
I Patient survival and quality of life are two very important 
 factors in the selection of a dialysis modality
I The majority of studies have compared the two modalities as 
‘competitors’ rather than as ‘complementary’ techniques
I Since every RRT has a technical ‘drop-out’, it is very likely that 
a patient will need several modalities during his lifetime and 
transfer from one technique to another will often be needed
I Survival studies of patients on RRT should evaluate ‘the best 
therapeutic strategy’, i.e. the succession of modalities that:
–   Allows an optimal total survival
–   Utilizes the specific advantages of each modality at any 
 given moment of the patient’s life in an optimal way
–   Avoids the drawbacks of each modality as much as possi-
ble
I Appropriate statistical statistics should be applied for correct 
analysis
 Fig. 6. Different modalities of renal replacement therapy. 
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